Boiron SA (EPA:BOI)

Market Cap	494.82M +17.0%
Revenue (ttm)	501.11M +2.8%
Net Income	32.64M +188.0%
EPS	1.88 +188.0%
Shares Out	17.36M
PE Ratio	15.16
Forward PE	13.87
Dividend	1.35 (4.74%)
Ex-Dividend Date	Jun 3, 2026

Volume	7,224
Average Volume	5,064
Open	28.50
Previous Close	28.50
Day's Range	28.50 - 29.50
52-Week Range	20.85 - 32.25
Beta	0.23
RSI	62.77
Earnings Date	Jul 17, 2026

About Boiron

Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1932
• Employees: 2,634
• Stock Exchange: Euronext Paris
• Ticker Symbol: BOI

Financial Performance

In 2025, Boiron's revenue was 501.11 million, an increase of 2.78% compared to the previous year's 487.56 million. Earnings were 32.64 million, an increase of 187.96%.